The Lifetime Medical Cost Savings From Preventing HIV in the United States
Open accessThe DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Enhanced HIV prevention interventions, such as preexposure prophylaxis for high-risk individuals, require substantial investments. We sought to estimate the medical cost saved by averting 1 HIV infection in the United States. METHODS: We estimated lifetime medical costs in persons with and without HIV to determine the cost saved by preventing 1 HIV infection. We used a computer simulation model of HIV disease and treatment (CEPAC) to project CD4 cell count, antiretroviral treatment status, and mortality after HIV infection. Annual medical cost estimates for HIV-infected persons, adjusted for age, sex, race/ethnicity, and transmission risk group, were from the HIV Research Network (range, $1854-$4545/mo) and for HIV-uninfected persons were from the Medical Expenditure Panel Survey (range, $73-$628/mo). Results are reported as lifetime medical costs from the US health system perspective discounted at 3% (2012 USD). RESULTS: The estimated discounted lifetime cost for persons who become HIV infected at age 35 is $326,500 (60% for antiretroviral medications, 15% for other medications, 25% nondrug costs). For individuals who remain uninfected but at high risk for infection, the discounted lifetime cost estimate is $96,700. The medical cost saved by avoiding 1 HIV infection is $229,800. The cost saved would reach $338,400 if all HIV-infected individuals presented early and remained in care. Cost savings are higher taking into account secondary infections avoided and lower if HIV infections are temporarily delayed rather than permanently avoided. CONCLUSIONS: The economic value of HIV prevention in the United States is substantial given the high cost of HIV disease treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The lifetime medical cost savings from preventing one HIV infection is estimated to be $389,359 (Schackman et al., 2015).”
From Monetary conversion factors for economic evaluations of substance use disorders (2017) · cites this paper as Schackman et al., 2015
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
Palella, F. J., Baker, R. K., Moorman, A. C., Chmiel, J. S., Wood, K. C., Brooks, J. T., & Holmberg, S. D. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000233310.90484.16 · Cited by 1,350 · cited 6×
“To calculate annual medical costs of HIV-uninfected individuals, we used data from the MEPS, a nationally representative survey of households in the United States.21 Using the online MEPS query tool,21 we calculated the mean annual medical care expenditures from the MEPS household survey in 2009 stratified by sex, rac…”
InfluentialKaplan, J. E., Benson, C., Holmes, K. K., Brooks, J. T., Pau, A., & Masur, H. (2009) · PsycEXTRA Dataset · doi:10.1037/e537722009-001 · Cited by 1,343
Estimated HIV Incidence in the United States, 2006–2009
Prejean, J., Song, R., Hernandez, A., Ziebell, R., Green, T., Walker, F., Lin, L. S., An, Q., Mermin, J., Lansky, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017502 · Cited by 1,071 · cited 8×
“To calculate annual medical costs of HIV-uninfected individuals, we used data from the MEPS, a nationally representative survey of households in the United States.21 Using the online MEPS query tool,21 we calculated the mean annual medical care expenditures from the MEPS household survey in 2009 stratified by sex, rac…”
InfluentialHIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity.
Deeks, S. G., & Phillips, A. N. (2009) · BMJ · doi:10.1136/bmj.a3172 · Cited by 704
National Technical Information Service
(2008) · Reference Reviews · doi:10.1108/09504120810872238 · Cited by 611
High, K. P., Brennan-Ing, M., Clifford, D. B., Cohen, M. H., Currier, J., Deeks, S. G., Deren, S., Effros, R. B., Gebo, K., Goronzy, J. J., et al. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31825a3668 · Cited by 522 · cited 1×
“We found that non-HIV chronic care medications represent a substantial component of cost as well, emphasizing the significant cost of managing non-HIV comorbidities in an aging HIV-infected population.(13,47) These comorbidities are frequently managed by HIV primary care providers.”
Self-citationThe Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease
Freedberg, K. A., Losina, E., Weinstein, M. C., Paltiel, A. D., Cohen, C. J., Seage, G. R., Craven, D. E., Zhang, H., Kimmel, A. D., & Goldie, S. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441108 · Cited by 508 · cited 1×
“For HIV-infected persons, we projected mortality and immune function (CD4 count distribution) using the CostEffectiveness of Preventing AIDS Complications (CEPAC) model, a widely published state-transition model of HIV disease.(7,16,17) Annual medical costs were estimated using data from the HIV Research Network (HIVR…”
MethodSelf-citationSax, P. E., DeJesus, E., Mills, A., Zolopa, A., Cohen, C., Wohl, D., Gallant, J. E., Liu, H. C., Zhong, L., Yale, K., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60917-9 · Cited by 444
Research works printed but not linked: 4
- US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2014 clinical practice guideline. Center for Disease Control and Prevention; [Accessed May 6, 2014]. Available at: <http://www.cdc.gov/hiv/pdf/PrEPguidelines2014.pdf>. [[Google Scholar](https://scholar.google.com/scholar_lookup?title=Preexposure%20prophylaxis%20for%20the%20prevention%20of%20HIV%20infection%20in%20the%20United%20States%20-%202014%20clinical%20practice%20guideline&)]
- Cost-effectiveness of preventing AIDS complications. Massachusetts General Hospital; [Accessed December 18, 2013]. Available at: <http://web2.research.partners.org/cepac/mainpage.html>. [[Google Scholar](https://scholar.google.com/scholar_lookup?title=Cost-effectiveness%20of%20preventing%20AIDS%20complications&)]
- Red Book. Montvale, NJ: Thompson PDR; 2009. [[Google Scholar](https://scholar.google.com/scholar_lookup?title=Red%20Book&publication_year=2009&)]
- Althoff KN. Personal communication to K. Gebo requesting NA-ACCORD data for CD4 count at presentation to care stratified by race, sex, and risk group (2007 data) 2012 [[Google Scholar](https://scholar.google.com/scholar_lookup?Althoff%20KN.%20Personal%20communication%20to%20K.%20Gebo%20requesting%20NA-ACCORD%20data%20for%20CD4%20count%20at%20presentation%20to%20care%20stratified%20by%20race,%20sex,%20and%20risk%20group%20(2007%20data)%202012)]
Cited by
van Heuvel, Y., Schatz, S., Rosengarten, J. F., & Stitz, J. (2022) · Toxins · doi:10.3390/toxins14020138 · Cited by 170
“Accordingly, HIV treatment in the Western world reveals high lifetime costs of at least USD 326,500 for an individual who acquires HIV at the age of 35 as estimated by a US study from 2015 [152].”
BackgroundEstimated Lifetime Economic Burden of Type 1 Diabetes
Sussman, M., Benner, J., Haller, M. J., Rewers, M., & Griffiths, R. I. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0398 · Cited by 104
“37 Similarly, Romley et al. assessed the impact of earlier initiation of combination antiretroviral therapy in the course of HIV (compared to later initiation), and found those who initiated treatment early had life expectancy gains between 6 and 9 years, depending on the CD4 count upon treatment…”
Estimated Lifetime HIV–Related Medical Costs in the United States
Bingham, A., Shrestha, R. K., Khurana, N., Jacobson, E. U., & Farnham, P. G. (2021) · Sexually Transmitted Diseases · doi:10.1097/olq.0000000000001366 · Cited by 87
Kugler, K. C., Guastaferro, K., Shenk, C. E., Beal, S. J., Zadzora, K. M., & Noll, J. G. (2018) · Child Abuse & Neglect · doi:10.1016/j.chiabu.2018.06.005 · Cited by 85
“For example, the cost of pregnancy and child birth among teens is estimated to exceed $9 billion (Hoffman, 2013) and treatment of STIs, including HIV, requires a lifetime commitment to therapies (Schackman et al., 2015).”
BackgroundTasillo, A., Salomon, J. A., Trikalinos, T. A., Horsburgh, C. R., Marks, S. M., & Linas, B. P. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.3941 · Cited by 80
“The FB-HIV population has a life expectancy without LTBI of 69 years.(4,6) The FB-D population has a life expectancy without LTBI of 75 years.”
Metadata
- Authors
- Schackman, B. R., Fleishman, J. A., Su, A. E., Berkowitz, B. K., Moore, R. D., Walensky, R. P., Becker, J. E., Voss, C., Paltiel, A. D., Weinstein, M. C., Freedberg, K. A., Gebo, K. A., & Losina, E.
- Affiliations
- Brigham and Women's Hospital (US)
- Agency for Healthcare Research and Quality (US)
- Massachusetts General Hospital (US)
- Johns Hopkins University (US)
- Corresponding author
- Schackman, Bruce R.
- Walensky, Rochelle P.
- ORCID
- Venue
- Medical Care
- Published
- 2015-04
- Volume
- 53
- Issue
- 4
- Pages
- 293-301
- ISSN
- 0025-7079 (ISSN-L)
- PMC
- PMC4359630
- OpenAlex
- W2049404409
- Cited by
- 123
- References
- 44
- Citations by year
- 2026: 9 · 2025: 9 · 2024: 7 · 2023: 8 · 2022: 9 · 2021: 11 · 2020: 14 · 2019: 19 · 2018: 12 · 2017: 10 · 2016: 8 · 2015: 6
- FWCI
- 9.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Medical Care (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Public Health Service (HHSA 290-2011-00007C, HHSH250201200008C)
- National Institute of Mental Health (R25MH094612)
- National Institute of Allergy and Infectious Diseases (R37 AI42006, R37AI042006, P30AI094189)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
- Keywords
- HIV prevention, lifetime medical costs, cost reduction, pre-exposure prophylaxis, antiretroviral therapy, HIV disease progression, CD4 count, HIV mortality, secondary infection
- MeSH terms
- Adolescent, Adult, Computer Simulation, Humans, Middle Aged, United States, HIV Infections, Cost Savings, Health Care Costs, CD4 Lymphocyte Count, Models, Economic, Anti-Retroviral Agents, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Lifetime Medical Cost Savings From Preventing HIV in the United States. https://app.cochat.ai/papers/10.1097/mlr.0000000000000308
- The paper
- Schackman, B. R., Fleishman, J. A., Su, A. E., Berkowitz, B. K., Moore, R. D., Walensky, R. P., Becker, J. E., Voss, C., Paltiel, A. D., Weinstein, M. C., Freedberg, K. A., Gebo, K. A., & Losina, E. (2015). The Lifetime Medical Cost Savings From Preventing HIV in the United States. Medical Care. https://doi.org/10.1097/mlr.0000000000000308
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.